文献速递骨软组织肉瘤与黑色素瘤

Eag1在骨肉瘤中的表达及其调控恶性表型的分子机制

[Expression of Ether à go-go 1 and its molecular mechanism of regulating the malignant phenotype of osteosarcoma].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2016-01-01

研究检测Eag1在骨肉瘤细胞系和人骨肉瘤组织中的表达,用siRNA抑制Eag1后观察细胞增殖、侵袭、迁移及裸鼠移植瘤生长,并检测VEGF与STAT3表达。结果显示Eag1在骨肉瘤细胞和组织中高表达,抑制Eag1可降低细胞存活率、集落形成率、侵袭细胞数和迁移率,并减小移植瘤体积,同时VEGF与STAT3表达下降。作者认为Eag1可能通过STAT3-VEGF通路促进骨肉瘤细胞增殖和侵袭,可能是潜在治疗靶点。

要点

  • Eag1在骨肉瘤细胞系和人骨肉瘤组织中高表达。
  • Eag1 siRNA降低两株骨肉瘤细胞的存活率、集落形成率、侵袭细胞数和迁移率。
  • Eag1 siRNA减小裸鼠骨肉瘤移植瘤体积,并下调VEGF与STAT3表达。

核心结论

  • 作者认为Eag1可能通过靶向STAT3-VEGF通路促进骨肉瘤细胞增殖和侵袭,可能是骨肉瘤的潜在治疗靶点。

研究设计与样本

  • 体外研究:用RT-PCR、蛋白质印迹和免疫组化检测Eag1在骨肉瘤细胞系和人骨肉瘤组织中的表达,并用siRNA抑制Eag1。
  • 用CCK-8、集落形成实验、Transwell实验和划痕愈合实验检测转染Eag1 siRNA的骨肉瘤细胞的增殖和侵袭能力。
  • 建立裸鼠骨肉瘤移植瘤模型并绘制肿瘤生长曲线,用蛋白质印迹检测转染Eag1 siRNA的骨肉瘤细胞中VEGF和STAT3的表达。

主要发现

  • Eag1在骨肉瘤细胞和组织中高表达。
  • MG-63细胞存活率:scrambled siRNA组(100.0±4.65)%,Eag1 siRNA1组(63.57±3.89)%,Eag1 siRNA2组(54.13±3.70)%;Saos-2细胞:scrambled siRNA组(100.00±5.46)%,Eag1 siRNA1组(56.70±5.34)%,Eag1 siRNA2组(40.27±5.28)%,均P<0.001。
  • MG-63细胞集落形成率:scrambled siRNA组(92.00±3.46)%,Eag1 siRNA1组(60.00±3.06)%,Eag1 siRNA2组(53.67±2.40)%;Saos-2细胞:scrambled siRNA组(92.00±5.57)%,Eag1 siRNA1组(52.33±5.13)%,Eag1 siRNA2组(41.67±2.73)%,均P<0.001。
  • 治疗10天后,Eag1 siRNA1组和Eag1 siRNA2组骨肉瘤移植瘤体积均显著小于scrambled siRNA组(均P<0.01)。
  • MG-63侵袭细胞数:scrambled siRNA组134.00±3.61,Eag1 siRNA1组105.20±2.52,Eag1 siRNA2组91.00±3.01;Saos-2:scrambled siRNA组132.30±3.23,Eag1 siRNA1组114.30±3.48,Eag1 siRNA2组82.67±6.33,均P<0.01。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the expression of ether à go-go 1 (Eag1) in human osteosarcoma and its molecular mechanisms of regulating the malignant phenotype of osteosarcoma. Methods: The expression levels of Eag1 in osteosarcoma cell lines and human osteosarcoma tissues were detected by reverse transcription polymerase chain reaction (RT-PCR), western blot analysis and immunohistochemistry. The small interfering RNA (siRNA) was used to inhibit the expression of Eag1. The abilities of proliferation and invasion in osteosarcoma cells transfected with Eag1 siRNA were determined by CCK-8, colony formation assay, transwell assay and wound healing assay. The osteosarcoma xenograft model of nude mouse was established and tumor growth curve was drawn. Western blot analysis was performed to detect the expression of vascular endothelial growth factor (VEGF) and signal transducer and activator of transcription 3 (STAT3) in osteosarcoma cells transfected with Eag1 siRNAs. Results: Eag1 was overexpressed in the osteosarcoma cells and tissues. Compared with the scrambled siRNA group, the cell survival rates of Eag1 siRNA1 and Eag1 siRNA2 groups of the two cell lines were significantly lower. [MG-63 cells: scrambled siRNA group (100.0±4.65)%, Eag1 siRNA1 group (63.57±3.89)%, and Eag1 siRNA2 group (54.13±3.70)%; Saos-2 cells: scrambled siRNA group (100.00±5.46)%, Eag1 siRNA1 group (56.70±5.34)%, and Eag1 siRNA2 group (40.27±5.28)% (P<0.001 for all)]. Similar results were obtained from colony formation assay. The colony formation rates of MG-63 cells: the scrambled siRNA group was (92.00±3.46)%, Eag1 siRNA1 group (60.00±3.06)%, and Eag1 siRNA2 group (53.67±2.40)%; the colony formation rates of Saos-2 cells: the scrambled siRNA group was (92.00±5.57)%, Eag1 siRNA1 group (52.33±5.13)%, and Eag1 siRNA2 group (41.67±2.73)%. Compared with the scrambled siRNA group, P<0.001 for all. The tumor volumes of osteosarcoma xenograft in the Eag1 siRNA1 and Eag1 siRNA2 groups were significantly smaller than that in the scrambled siRNA group after 10 days treatment (P<0.01 for all). The invasion assay data showed that MG-63 and Saos-2 cells transfected with Eag1 siRNAs exhibited the ability of cell invasion, when compared with the cells transfected with scrambled siRNA. (Invasive cell number of MG-63 cells: the scrambled siRNA group was 134.00±3.61, Eag1 siRNA1 group 105.20±2.52, and Eag1 siRNA2 group 91.00±3.01; Invasive cell number of Saos-2 cells: the scrambled siRNA group was 132.30±3.23, Eag1 siRNA1 group 114.30±3.48, and Eag1 siRNA2 group 82.67±6.33. Compared with the scrambled siRNA group, P<0.01 for all. The migration rates were (62.48±1.83)%, (35.98±1.23)% and (32.30±1.20)% in the three groups of MG-63 cells, and (70.15±1.42)%, (41.38±1.34)% and (32.40±1.92)% in the three groups of Saos-2 cells, respectively. Compared with the scrambled siRNA group, P<0.001 for all. Notably, the expression levels of VEGF decreased evidently after Eag1 siRNAs transfection, paralleled with reduction in the expression levels of STAT3. Conclusions: Eag1 may promote osteosarcoma cell proliferation and invasion by targeting STAT3-VEGF pathway and may be a potential therapeutic target for osteosarcoma.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Chen ZD, Liu QJ, Zeng WR, et al. [Expression of Ether à go-go 1 and its molecular mechanism of regulating the malignant phenotype of osteosarcoma]. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27998439. doi:10.3760/cma.j.issn.0253-3766.2016.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。